Using spatial navigation to detect early Alzheimer's disease.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore spatial navigation as a novel cognitive biomarker for the early detection of Alzheimer's Disease (AD). It focuses on patients with Mild Cognitive Impairment (MCI) and mild Alzheimer's dementia, as well as healthy controls, to assess their spatial navigation abilities through innovative testing methods. The study seeks to improve the ecological validity of current neuropsychological tests, which often fail to accurately reflect real-world navigation skills. By identifying early cognitive decline through spatial navigation, the research hopes to facilitate timely diagnosis and intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD)
* Patients with a mild Alzheimer's Dementia
* Patients with MCI without a formal dementia diagnosis
* Healthy controls

Exclusion Criteria:

* Diabetes (only for healthy controls)
* Epilepsy
* Presence of extreme depressive symptoms (\>11 on Geriatric depression scale or \>20 on Beck depression inventory)
* Presence of extreme anxiety (\>22 on Beck Anxiety Inventory)
* A major psychiatric of medical disorder
* Alcohol excess
* Moderate to severe white matter lesions on MRI (\>2 Fazekas)
* Any visual of mobility impairment of such severity as to compromise the ability to undertake the iVR task.

Where it's running

• University Hospital Gent
  Ghent, East-Flanders, Belgium Recruiting

Study contacts

• Principal investigator: Paul Boon, PhD — University Hospital, Ghent
• Study coordinator: Tineke Van Vrekhem, Master
• Email: Tineke.VanVrekhem@uzgent.be
• Phone: 093326483

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease

  A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07717567

• Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers

  This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.

  Recruiting Yale University · New Haven, Connecticut · NCT07602283

• Using ultra-high field and metabolic MRI to understand resilience and degeneration in the aging and diseased brain

  This project will try advanced 3T and 7T MRI scans, including sodium and phosphorus imaging, to see if metabolic and connectivity changes explain resilience and degeneration in adults with MS, NMOSD, MOGAD, Alzheimer’s, Parkinson’s, or healthy aging.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT07202494

• Fast-track screening to determine eligibility for anti-amyloid treatment using digital cognitive tests and blood biomarkers.

  This project will test whether combining self‑administered digital cognitive tests with blood biomarker results can quickly identify patients referred for memory concerns who may qualify for anti‑amyloid disease‑modifying therapy.

  Recruiting MoCA Clinic and Institute · Greenfield Park, Quebec · NCT07041450

• Ultralow-dose amyloid PET with 18F‑Florbetapir or 18F‑Flutemetamol

  This trial will try using a very small amount of an amyloid PET tracer with a high-sensitivity PET scanner to see if clear brain images can be made for people with Alzheimer’s, mild cognitive impairment, other dementias, and healthy volunteers.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07012993

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.